Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

LUNAR-2: TTFields con pembrolizumab + quimioterapia a base de platino para el NSCLC metastásico (LUNAR-2)

5 de noviembre de 2026 actualizado por: NovoCure GmbH

LUNAR-2: estudio fundamental, aleatorizado y abierto de campos de tratamiento de tumores (TTFields, 150 kHz) concomitantes con pembrolizumab y quimioterapia a base de platino para el tratamiento del cáncer de pulmón de células no pequeñas metastásico

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Descripción general del estudio

Descripción detallada

LUNAR-2 is a pivotal, randomized, open-label study that aims to evaluate the effectiveness and safety of Tumor Treating Fields (TTFields) concomitantly administered with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC).

The primary objectives of the study are to assess overall survival (OS) and progression-free survival (PFS) in subjects treated with TTFields, pembrolizumab, and platinum-based chemotherapy compared to those treated with pembrolizumab and platinum-based chemotherapy alone. PFS will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

The secondary endpoints of this study will evaluate PFS and OS, stratified by the specific histological subtype of NSCLC and PD-L1 Tumor Proportion Score (TPS).

The population will consist of subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and will be stratified as follow:

  1. Histology - Squamous vs. non-squamous
  2. PD-L1 expression level - TPS <1% vs. 1% ≤TPS <50% vs. TPS ≥50%
  3. Prior treatment with immunotherapy - yes vs. no

The study will be conducted globally at approximately 130 participating sites. The study device, NovoTTF-200T, is a portable, battery-operated system that delivers TTFields at a frequency of 150kHz. It utilizes insulated transducer arrays to deliver electric forces intended to disrupt cancer cell division.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

734

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Berlin, Alemania, 13125
        • Reclutamiento
        • Evangelische Lungenklinik Berlin
        • Contacto:
      • Giessen, Alemania, 35392
      • Halle, Alemania, 06120
        • Reclutamiento
        • Krankenhaus Martha-Maria Halle-Dolau
        • Investigador principal:
          • Wolfgang Schuette
        • Contacto:
      • Heidelberg, Alemania, 69126
      • Löwenstein, Alemania, 74245
        • Reclutamiento
        • Klinik Loewenstein gGmbH
        • Contacto:
      • Oldenburg, Alemania, 26121
      • Innsbruck, Austria, 6020
        • Reclutamiento
        • Universitaetsklinik fuer Innere Medizin V Innsbruck
        • Contacto:
      • Salzburg, Austria, 5020
        • Reclutamiento
        • University Hospital Salzburg
        • Contacto:
          • Richard Greil
          • Número de teléfono: 43-662-4482 4100
          • Correo electrónico: r.greil@salk.at
      • Vienna, Austria, 1210
        • Reclutamiento
        • Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf
        • Contacto:
      • Brussels, Bélgica, 1200
        • Reclutamiento
        • Cliniques universitaires Saint-Luc
        • Contacto:
      • Ghent, Bélgica, 9000
        • Reclutamiento
        • AZ Maria Middelares - Campus Maria Middelares
        • Contacto:
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 1Z2
        • Reclutamiento
        • Cross Cancer Institute/University of Alberta
        • Contacto:
        • Investigador principal:
          • Haidar El Darsa
    • Ontario
      • Ottawa, Ontario, Canadá, K1H 8L6
        • Reclutamiento
        • The Ottawa Hospital Cancer Centre General Campus
        • Investigador principal:
          • Garth Nicholas
        • Contacto:
          • Garth Nicholas
          • Número de teléfono: 70175 613-737-7700
          • Correo electrónico: gnicholas@toh.ca
      • Toronto, Ontario, Canadá, M4N 3M5
        • Reclutamiento
        • Sunnybrook Health Sciences Center
        • Contacto:
        • Investigador principal:
          • Susanna Cheng
    • Quebec
      • Montreal, Quebec, Canadá, H2L 4M1
        • Reclutamiento
        • CHUM
        • Investigador principal:
          • David Roberge
        • Contacto:
      • Olomouc, Chequia, 779 00
        • Reclutamiento
        • Fakultni nemocnice Olomouc FNOL
        • Contacto:
      • Ostrava, Chequia, 70300
        • Reclutamiento
        • Nemocnice Agel Ostrava-Vitkovice / Agel Ostrava-Vitkovice Hospital
        • Contacto:
      • Prague, Chequia, 12808
        • Reclutamiento
        • General University Hospital in Prague
        • Contacto:
      • Barcelona, España, 8916
        • Reclutamiento
        • Institut Catala d'Oncologia
        • Contacto:
      • Lleida, España, 25198
        • Reclutamiento
        • Hospital Universitario Arnau de Vilanova
        • Contacto:
      • Madrid, España, 28034
        • Reclutamiento
        • Hospital Ruber Internacional
        • Contacto:
      • Madrid, España, 28027
        • Reclutamiento
        • Clinica Universidad de Navarra (Madrid)
        • Contacto:
          • Miguel Fernandez de Sanmamed Gutierrez
          • Número de teléfono: +34 948255400
          • Correo electrónico: msanmamed@unav.es
      • Málaga, España, 29010
        • Reclutamiento
        • Hospital Regional Universitario de Malaga
        • Contacto:
      • Pamplona, España, 31008
        • Reclutamiento
        • Clinica Universidad de Navarra
        • Contacto:
          • Miguel Fernandez de Sanmamed Gutierrez
          • Número de teléfono: +34 948255400
          • Correo electrónico: msanmamed@unav.es
    • Alicante
      • Elche, Alicante, España, 3293
        • Reclutamiento
        • Hospital Universitario del Vinalopo
        • Contacto:
    • Andalusia
      • Seville, Andalusia, España, 41013
        • Reclutamiento
        • Hospital Universitario Virgen del Rocio
        • Contacto:
          • Carlos Cabrera
          • Número de teléfono: +34 932 287 445
          • Correo electrónico: ccabrera@uomi.es
    • Catalonia
      • Barcelona, Catalonia, España, 8017
        • Reclutamiento
        • Clinica Mi Tres Torres Barcelona - Giromed Institute
        • Contacto:
          • Carlos Cabrera Galvez
          • Número de teléfono: +34 932 287 445
          • Correo electrónico: ccabrera@uomi.es
    • Madrid
      • Torrejón de Ardoz, Madrid, España, 28850
        • Reclutamiento
        • Hospital Universitario de Torrejon
        • Contacto:
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35209
    • Arizona
      • Goodyear, Arizona, Estados Unidos, 85338
        • Reclutamiento
        • Western Regional Medical Center, LLC
        • Contacto:
    • California
      • Fullerton, California, Estados Unidos, 92835
        • Reclutamiento
        • St. Jude Herritage Medical Group
        • Contacto:
      • Newport Beach, California, Estados Unidos, 92663
        • Reclutamiento
        • Hoag Family Cancer Institute - Hoag Memorial Hospital
        • Contacto:
      • Sacramento, California, Estados Unidos, 95816
        • Reclutamiento
        • Sutter Institute for Medical Research
        • Contacto:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32207
        • Reclutamiento
        • Baptist MD Anderson Cancer Center, Baptist Health
        • Contacto:
        • Investigador principal:
          • John Vu
      • Ocala, Florida, Estados Unidos, 34474
        • Reclutamiento
        • Florida Cancer Affiliates - Ocala Oncology
        • Contacto:
      • Tampa, Florida, Estados Unidos, 33612
        • Reclutamiento
        • Moffitt Cancer Center
        • Contacto:
    • Illinois
      • Barrington, Illinois, Estados Unidos, 60010
        • Reclutamiento
        • Northwest Oncology & Hematology
        • Contacto:
      • Elmhurst, Illinois, Estados Unidos, 60126
        • Reclutamiento
        • Elmhurst Hospital Nancy Knowles Cancer Center
        • Contacto:
      • Naperville, Illinois, Estados Unidos, 60540-6766
        • Reclutamiento
        • Edward Cancer Center
        • Contacto:
      • Zion, Illinois, Estados Unidos, 60099
        • Reclutamiento
        • Cancer Treatment Centers of America (CTCA)
        • Contacto:
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46845
        • Reclutamiento
        • Parkview Packnett Family Cancer Institute
        • Investigador principal:
          • Brian Chang
        • Contacto:
      • Indianapolis, Indiana, Estados Unidos, 46237
    • Kansas
      • Westwood, Kansas, Estados Unidos, 66205
        • Reclutamiento
        • University of Kansas Cancer Center
        • Contacto:
    • Missouri
      • Annapolis, Missouri, Estados Unidos, 21401
        • Reclutamiento
        • Luminis Health Radiation Oncology - Anne Arundel Health System
        • Contacto:
      • Kansas City, Missouri, Estados Unidos, 64154
        • Reclutamiento
        • University of Kansas Cancer Center - North
        • Contacto:
      • Lee's Summit, Missouri, Estados Unidos, 64064
        • Reclutamiento
        • University of Kansas Cancer Center - Lee's Summit
        • Contacto:
      • Overland, Missouri, Estados Unidos, 66210
        • Reclutamiento
        • University of Kansas Cancer Center - Overland Park
        • Contacto:
    • New York
      • New Hyde Park, New York, Estados Unidos, 11042
        • Reclutamiento
        • New York Cancer & Blood Specialists (NYCBS)
        • Contacto:
      • New York, New York, Estados Unidos, 10028
        • Reclutamiento
        • New York Cancer & Blood Specialists (NYCBS)
        • Contacto:
      • Rochester, New York, Estados Unidos, 14642
        • Reclutamiento
        • University of Rochester Medical Center
        • Contacto:
      • Shirley, New York, Estados Unidos, 19967
        • Reclutamiento
        • New York Cancer & Blood Specialists (NYCBS)
        • Contacto:
      • The Bronx, New York, Estados Unidos, 10469
        • Reclutamiento
        • New York Cancer & Blood Specialists (NYCBS)
        • Contacto:
    • North Carolina
      • Cary, North Carolina, Estados Unidos, 27518
        • Reclutamiento
        • WakeMed Health & Hospitals
        • Contacto:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212
        • Reclutamiento
        • AHN Cancer Center
        • Contacto:
    • Texas
      • Dallas, Texas, Estados Unidos, 75235
      • Dallas, Texas, Estados Unidos, 75235
        • Reclutamiento
        • Old Parkland Hospital Hematology Oncology Clinic
        • Contacto:
      • Edinburg, Texas, Estados Unidos, 78539
        • Reclutamiento
        • DHR Health Oncology Institute
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Houston Methodist Cancer Center
        • Investigador principal:
          • Jun Zhang
        • Contacto:
      • Richardson, Texas, Estados Unidos, 75082
        • Reclutamiento
        • Methodist Richardson Cancer Center
        • Contacto:
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • Jason Bates at University of Texas Health Science Center
        • Contacto:
    • Washington
      • Auburn, Washington, Estados Unidos, 98001
        • Reclutamiento
        • MultiCare Regional Cancer Center
        • Contacto:
      • Gig Harbor, Washington, Estados Unidos, 98335
        • Reclutamiento
        • MultiCare Regional Cancer Center
        • Contacto:
      • Puyallup, Washington, Estados Unidos, 98372
        • Reclutamiento
        • MultiCare Regional Cancer Center
        • Contacto:
      • Spokane, Washington, Estados Unidos, 99218
        • Reclutamiento
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
        • Contacto:
      • Tacoma, Washington, Estados Unidos, 98405
        • Reclutamiento
        • MultiCare Institute for Research & Innovation
        • Contacto:
      • Créteil, Francia, 94010
        • Reclutamiento
        • Centre Hospitalier Intercommunal de Creteil
        • Contacto:
      • Limoges, Francia, 87000
        • Reclutamiento
        • CHU Limoges
        • Investigador principal:
          • Thomas Egenod
        • Contacto:
      • Marseille, Francia, 13003
        • Reclutamiento
        • Hopital Europeen
        • Contacto:
      • Nantes, Francia, 44277
        • Reclutamiento
        • Hopital Prive du Confluent
        • Investigador principal:
          • Cyriac Blonz
        • Contacto:
      • Paris, Francia, 75005
        • Reclutamiento
        • Institut Curie
        • Contacto:
      • Pessac, Francia, 33604
        • Reclutamiento
        • CHU de Bordeaux
        • Contacto:
      • Pierre-Bénite, Francia, 69495
        • Reclutamiento
        • Centre Hospitalier Lyon Sud
        • Contacto:
      • Strasbourg, Francia, 67091
      • Farkasgyepű, Hungría, 8582
        • Reclutamiento
        • Farkasgyepui Tudogyogyintezet
        • Contacto:
      • Kecskemét, Hungría, 6000
        • Reclutamiento
        • Bacs-Kiskun Varmegyei Oktatokorhaz
        • Contacto:
      • Szekszárd, Hungría, 7100
        • Reclutamiento
        • Tolna Varmegyei Balassa Janos Korhaz
        • Contacto:
          • Yousuf Al-Farhat
          • Número de teléfono: +36 30 644 1744
          • Correo electrónico: yalfarhat@gmail.com
      • Afula, Israel, 1834111
        • Reclutamiento
        • Emek Medical Center
        • Contacto:
      • Haifa, Israel, 34561
        • Reclutamiento
        • Bnai zion MC
        • Contacto:
      • Alessandria, Italia, 15121
        • Reclutamiento
        • A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria
        • Contacto:
        • Contacto:
      • Bergamo, Italia, 24125
        • Reclutamiento
        • Humanitas Gavazzeni
        • Contacto:
      • Ferrara, Italia, 44124
        • Reclutamiento
        • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
        • Contacto:
      • Meldola, Italia, 47014
        • Reclutamiento
        • IRCCS - Istituto Romagnolo per lo Studio Dei Tumori, Dino Amadori
        • Contacto:
      • Pesaro, Italia, 61122
        • Reclutamiento
        • Azienda Sanitaria Territoriale Pesaro Urbino
        • Contacto:
      • Roma, Italia, 00128
        • Reclutamiento
        • Universita Campus Bio-Medico di Roma (UCBM) - Policlinico Universitario
        • Contacto:
      • Rome, Italia, 00186
      • Siena, Italia, 53100
        • Reclutamiento
        • Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
        • Contacto:
          • Michele Maio
          • Número de teléfono: 00390577586336
          • Correo electrónico: maio@unisi.it
    • Osaka
      • Osaka, Osaka, Japón, 541-8567
        • Reclutamiento
        • Osaka International Cancer Institute
        • Contacto:
        • Investigador principal:
          • Kei Kunimasa
      • Sakai, Osaka, Japón, 590-0197
        • Reclutamiento
        • Kindai University Hospital
        • Investigador principal:
          • Hidetoshi Hayashi
        • Contacto:
    • Saitama
      • Hidaka, Saitama, Japón, 350-1298
        • Reclutamiento
        • Saitama Medical University International Medical Center
        • Contacto:
          • Saitama Medical University International Medical Center
          • Número de teléfono: 042-984-4183
          • Correo electrónico: chikenme@saitama-med.ac.jp
    • Tokyo
      • Bunkyo, Tokyo, Japón, 113-8431
        • Reclutamiento
        • Juntendo University
        • Investigador principal:
          • Takehito Shukuya
        • Contacto:
      • Chuo-ku, Tokyo, Japón, 104-0045
        • Reclutamiento
        • National Cancer Center Hospital
        • Investigador principal:
          • Hidehito Horinouchi
        • Contacto:
          • Hidehito Horinouchi
          • Número de teléfono: 81-3542-2511
          • Correo electrónico: hhorinou@ncc.go.jp
      • Arnhem, Países Bajos, 6815AD
        • Reclutamiento
        • Rijnstate Ziekenhuis
        • Contacto:
      • Friesland, Países Bajos, 8934 AD
        • Reclutamiento
        • Medisch Centrum Leeuwarden (MCL) - Oncologisch Centrum Leeuwarden (OCL)
        • Contacto:
          • Johanna Hellinga
          • Número de teléfono: 0031 58 286 3768
          • Correo electrónico: Johanna.Post@mcl.nl
      • Harderwijk, Países Bajos, 3844 DG
        • Reclutamiento
        • St. Jansdal ziekenhuis
        • Contacto:
      • Utrecht, Países Bajos, 3543 AZ
      • Poznan, Polonia, 60-693
        • Reclutamiento
        • Uniwersytecki Szpital Kliniczny
        • Contacto:
    • Greater London
      • London, Greater London, Reino Unido
        • Reclutamiento
        • Charing Cross Hospital
        • Contacto:
        • Investigador principal:
          • Waleed Mohammed
    • Leicestershire
      • Leicester, Leicestershire, Reino Unido, LE1 5WW
        • Reclutamiento
        • University Hospitals of Leicester NHS Trust
        • Contacto:
        • Investigador principal:
          • Sean Dulloo
    • London
      • London, London, Reino Unido, SW3 6JJ
        • Reclutamiento
        • The Royal Marsden NHS Foundation Trust
        • Contacto:
    • Merseyside
      • Liverpool, Merseyside, Reino Unido, L7 8YA
        • Reclutamiento
        • Clatterbridge Cancer Centre - Liverpool
        • Investigador principal:
          • Carles Escriu
        • Contacto:
    • Sutton
      • Sutton, Sutton, Reino Unido, SM2 5PT
        • Reclutamiento
        • The Royal Marsden NHS Foundation Trust - Sutton
        • Contacto:
      • Singapore, Singapur, 329563
        • Reclutamiento
        • Curie Oncology
        • Contacto:
      • Singapore, Singapur, 168583
      • Singapore, Singapur, 574623
        • Reclutamiento
        • Icon Cancer Centre Singapore (Singapore Oncology Consultants)
        • Contacto:
      • Baden, Suiza, 5404
      • Fribourg, Suiza, 1752
        • Reclutamiento
        • HFR Freiburg-Kantonsspital
        • Investigador principal:
          • Alessandra Curioni-Fontecedro
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

  • ≥22 years of age in the USA

    ≥18 years of age outside of the USA.

  • Histologically or cytologically diagnosis of stage 4 (according to Version 8 of the American Joint Committee on Cancer [AJCC] criteria) non-squamous or squamous NSCLC.

  • Evaluable (measurable or non-measurable) disease in the thorax per RECIST v1.1.

  • Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.

  • ECOG Performance Status (PS) of 0-1.

  • Adequate hematologic and end-organ function

    o For subjects not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN (unless participant is receiving anticoagulant therapy as long as INR or aPTT is within therapeutic range of intended use of anticoagulants).

  • A female participant is eligible to participate if she is not pregnant, not breastfeeding

  • If male subject with a female partner(s) of child-bearing potential, must agree to use an effective contraception

  • All subjects must sign written informed consent.

Exclusion Criteria:

All individuals meeting any of the following exclusion criteria will be excluded from study participation:

  • Mixed small cell and NSCLC histology.

  • EGFR sensitizing mutation and/or ALK translocation, and/or ROS1 and/or RET targetable gene rearrangement, and/or METex14 skipping mutation, and/or NTRK1/2 gene fusion and/or BRAF V600 mutations directed therapy is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.

  • Has received systemic therapy for metastatic disease.

  • Had major surgery <3 weeks prior to randomization

  • Received radiation therapy to the lung that is > 30 Gy within 6 months of randomization.

  • Has received prior radiotherapy within 2 weeks of randomization. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.

  • Is expected to require any other form of antineoplastic therapy while on study.

  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.

    • Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
  • Has symptomatic Central Nervous System (CNS) metastases and/or carcinomatous meningitis. Subjects with asymptomatic CNS metastases or with previously treated brain metastases may participate provided they were treated before randomization (if applicable) and are neurologically stable and without requirement of steroid treatment for at least 7 days prior to randomization.

  • Has active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior randomization. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.

  • Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms in the 12 months prior to randomization.

  • Participation in another clinical study with an investigational agent or device during the 4 weeks prior to randomization.

  • Concurrent treatment with other experimental treatments for NSCLC while in the study.

  • Has a known sensitivity to any component of the planned systemic therapies (pembrolizumab, cisplatin/carboplatin, pemetrexed/paclitaxel/nab-paclitaxel) .

  • Pregnant or breastfeeding

  • Admitted to an institution by administrative or court order.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy

Subjects in this arm receive three treatments - TTFields using the NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy.

The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.

Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.

Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer

Comparador activo: Arm 2: Pembrolizumab and Platinum-based Chemotherapy

Subjects in this arm receive two treatments - pembrolizumab and platinum-based chemotherapy.

Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.

Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Survival (OS)
Periodo de tiempo: up to 6 years

To compare OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to OS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis).

up to 6 years
Progression Free Survival (PFS)
Periodo de tiempo: up to 6 years

To compare PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to PFS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis)

up to 6 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression Free Survival (PFS)
Periodo de tiempo: up to 6 years

Progression Free Survival (PFS) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology.

up to 6 years
Overall Survival (OS)
Periodo de tiempo: up to 6 years

Overall Survival (OS) in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology.

up to 6 years
Progression Free Survival (PFS)
Periodo de tiempo: up to 6 years

PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 Tumor Proportion Score (TPS).

up to 6 years
Overall Survival (OS)
Periodo de tiempo: up to 6 years

OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 TPS.

up to 6 years
Progression Free Survival (PFS)
Periodo de tiempo: up to 6 years

PFS per RECIST v1.1 as assessed by BICR at 6 (PFS6), 12 (PFS12), 24 (PFS24), and 36 (PFS36) months in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
1, 2, and 3-year Survival Rate
Periodo de tiempo: up to 6 years

1-, 2- and 3-year survival rate in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Objective Response Rate (ORR)
Periodo de tiempo: up to 6 years

Objective Response Rate (ORR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Duration of Response (DoR)
Periodo de tiempo: up to 6 years

Duration of Response (DoR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Disease Control Rate (DCR)
Periodo de tiempo: up to 6 years

Disease Control Rate (DCR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Progression Free Survival (PFS)
Periodo de tiempo: up to 6 years

PFS per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Objective Response Rate (ORR)
Periodo de tiempo: up to 6 years

ORR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Duration of Response (DoR)
Periodo de tiempo: up to 6 years

DoR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Disease Control Rate (DCR)
Periodo de tiempo: up to 6 years

DCR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Adverse Events
Periodo de tiempo: up to 6 years

Toxicity profile of TTFields concomitant with pembrolizumab and platinum-based chemotherapy. The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments.

up to 6 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de julio de 2024

Finalización primaria (Estimado)

1 de octubre de 2028

Finalización del estudio (Estimado)

1 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de diciembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

10 de enero de 2024

Publicado por primera vez (Actual)

22 de enero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de diciembre de 2025

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir